Drug Profile
Salbutamol dry-powder inhalation - sanofi-aventis
Alternative Names: Albuterol dry-powder inhalation - sanofi-aventis; Albuterol Ultrahaler; Salbutamol UltrahalerLatest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 26 Mar 2009 No development reported - Phase-III for Asthma in Europe (Inhalation)
- 26 Mar 2009 No development reported - Phase-III for Asthma in USA (Inhalation)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthélabo to form sanofi-aventis